

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/25983> holds various files of this Leiden University dissertation.

Author: Swartjes, Maarten

Title: Neuropathic pain and its treatment with ARA 290 and ketamine : overlapping pathways

Issue Date: 2014-06-12

Curriculum Vitae

Maarten Swartjes was born on 7 August 1985 in Nieuwegein. After attending Gymnasium, he started Biopharmaceutical Sciences in 2003 at Leiden University. He obtained his Bachelor's degree in 2006. In that same year, he started Medicine at Leiden University. Being interested in anesthesiology and research, he started in his first year as a student-assistant in clinical research at the department of Anesthesiology. In January 2008, he started working as a student assistant on the preclinical experiments in animal models of neuropathic pain, which allowed him to continue this work as a PhD student in January 2009. He continued to combine his PhD studentship with Medicine until he received his Doctorate's degree in June 2010. After that, he put his study on hold to finish the work described in this thesis. After the completion of the work for this thesis, he re-enrolled in Medicine for the rotations to complete his medical training.

List of publications

Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, Cerami A, Dahan A. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. *Molecular Pain* 2014; 10 (1): 13.

Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. *Molecular Medicine* 2013; 19: 334-45.

Brines M, Swartjes M, Tannemaat MR, Dunne A, van Velzen M, Proto P, Hoitsma E, Petropoulos I, Chen X, Niesters M, Dahan A, Malik R, Cerami A: Corneal nerve quantification predicts the severity of symptoms in sarcoidosis patients with painful neuropathy. *Technology* 2013; 1-7

Swartjes M, Niesters M, Heij L, Dunne A, Aarts L, Hand CC, Kim HS, Brines M, Cerami A, Dahan A. Ketamine does not produce relief of neuropathic pain in mice lacking the β -common receptor (CD131). *PLoS One* 2013; 8 (8): e71326.

Swartjes M, Niesters M, Dahan A. Assessment of allodynia relief by tissue-protective molecules in a rat model of nerve injury-induced neuropathic pain. *Methods in Molecular Biology* 2013; 982: 187-95.

Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. *Molecular Medicine* 2013;18: 1430-6.

Niesters M, Swartjes M, Heij L, Brines M, Cerami A, Dunne A, Hoitsma E, Dahan A: The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. *Expert Opinion on Orphan Drugs* 2013; 1: 77-87.

Swartjes M, Mooren RA, Waxman AR, Arout C, van de Wetering K, den Hartigh J, Beijnen JH, Kest B, Dahan A. Morphine induces hyperalgesia without involvement of μ -opioid receptor or morphine-3-glucuronide. *Molecular Medicine*. 2012; 18: 1320-6.

Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β -common receptor knockout mice. *Anesthesiology* 2011; 15 (5): 1084-92.

Swartjes M, Morariu A, Niesters M, Aarts L, Dahan A. Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain. *Anesthesiology* 2011; 115 (1): 165-74.

Noppers I, Niesters M, Swartjes M, Bauer M, Aarts L, Geleijnse N, Mooren R, Dahan A, Sarton E. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. *European Journal of Pain* 2011; 15 (9): 942-9.

Niesters M, Dahan A, Swartjes M, Noppers I, Fillingim RB, Aarts L, Sarton EY. Effect of ketamine on endogenous pain modulation in healthy volunteers. *Pain* 2011; 152 (3): 656-63.

Swartjes M, Niesters M, Sarton E, Morariu A, Cerami A, Aarts LPHJ, Dahan A. Weefselprotectie en preventie van chronische pijn. *A&I* 2010; 2 (3): 24-29.

